USPTO Patent Applications - Organic Chemistry (C07D)

COMPOUNDS AND USES THEREOF - Senolytic Compounds for Aging Treatment

The USPTO published patent application US20260097022A1 for senolytic compounds and methods for treating aging-related conditions. The application covers screening of 2,352 compounds for senolytic activity and trained neural networks to predict activity across over 800,000 molecules. Compounds disclosed bind to Bcl-2 proteins and reduce senescent cell burden. Application filed October 2, 2025; published April 9, 2026.

UV/HEV Light Filtering Compounds and Their Use

USPTO published patent application US20260098007A1 for compounds and their use in filtering ultraviolet (UV) and high-energy visible (HEV) light, invented by Micah Nelp and Anthony Young. The compounds may be used in compositions, consumer products, and packaging materials. This patent grant establishes intellectual property rights for the inventors.

Metalloenzyme Inhibitor Compounds (Patent Application US20260097034A1)

USPTO published patent application US20260097034A1 for metalloenzyme inhibitor compounds. The application was filed on October 2, 2025 (Application No. 19348647) by inventors Steven Sparks, Christopher M. Yates, Sammy R. Shaver, and William J. Hoekstra. The patent covers compounds having metalloenzyme modulating activity and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes.

Tetrahydroquinoline Compounds As Antitumor Agents

USPTO published patent application US20260097029A1 for tetrahydroquinoline compounds of Formula (I) and their salts as disruptors of the FANCM/BTR interaction, useful for hampering FANCM localization to telomeres in tumor treatment. The application (No. 19112485) was filed September 22, 2023 by inventors Sandro Cosconati, Stefano Tomassi, Salvatore Di Maro, and Hilda Amelia Pickett. CPC classifications include A61K 31/4709, A61P 35/00, and C07D 215/06.

Shionogi Fused Ring GLP-1 Receptor Agonist Patent Application

The USPTO published patent application US20260097037A1 by Shionogi & Co., Ltd. on April 9, 2026, covering fused ring compounds as GLP-1 receptor agonists for pharmaceutical use. The application was filed on September 21, 2023, under application number 19112403. The compounds are represented by formulas (I) and (II), with various substituents including phenyl groups and heterocyclic rings.

Fluoro Beta-Carboline Compounds, Bone Formation Method

USPTO published patent application US20260097041A1 for fluoro beta-carboline compounds and methods of promoting bone formation. The application (No. 19202018, filed May 8, 2025) covers compounds of Formula I and their use in orthopedic devices, periodontal devices, and treatment of renal disease, diabetes, bone loss, and cancer. Inventors include Debra Ellies, F. Scott Kimball, and Robert N. Young.

Plasmodium Falciparum Blood Stage Inhibitor Compounds for Malaria Treatment

USPTO published patent application US20260097046A1 disclosing compounds that inhibit Plasmodium falciparum asexual blood stage parasites for malaria treatment. The compounds exhibit sub-millimolar potency against intraerythrocytic stages and are soluble for oral administration. Inventors include Alicia N. Wagner, Roger Trombley, and 8 others. Application filed December 12, 2025.

Conjugates for Cancer Treatment - Patent Application US20260097117A1

USPTO published patent application US20260097117A1 for conjugates comprising a binding moiety and an immunomodulatory imide compound, such as substituted isoindoline compounds, useful for treating cancer. The application was filed October 2, 2025, by inventors Nathan Fishkin and Peter U. Park, with a publication date of April 9, 2026.

Tricyclic Heteroaryl Compounds as Inhibitors of TYK2 and/or JAK1

The USPTO published patent application US20260098044A1 for tricyclic heteroaryl compounds that inhibit TYK2 and/or JAK1 activity. The compounds are directed toward treating skin, respiratory, ophthalmic, and rectal diseases, cancer, and neuroinflammation. Inventors include Stacey Shepard, Onur Atasoylu, Song Mei, and Jun Pan, with application number 19348390 filed October 2, 2025.

Polycyclic Compound for Treatment of Abnormal Cell Proliferation Diseases

USPTO published patent application US20260098043A1 disclosing a polycyclic compound (CLM-L-PTM) or its pharmaceutical salt for treating abnormal cell proliferation diseases. The application names five inventors and covers pharmaceutical compositions suitable for preparing drugs targeting cell proliferation disorders.

GLP-1 Agonist Acid Salt Patent Application

The USPTO published patent application US20260098042A1 for a novel acid salt form of a GLP-1 receptor agonist (OAD2) invented by Haiwen HU, Li FANG, Fan HU, Xinjie ZHOU, and Fenfen CHEN. The compound is classified under CPC C07D 491/056 and may be useful in treating type 2 diabetes and metabolic disorders. The application was filed August 19, 2025, and published April 9, 2026.

Fused Bicyclic Pyrimidones as WRN Inhibitors

The USPTO published patent application US20260098041A1 assigned to Incyte Corporation, covering tricyclic pyrimidinones as inhibitors of WRN (Werner syndrome helicase). The application names nine inventors and describes pharmaceutical compositions useful in treating diseases or disorders such as cancer or infections. The application was filed on February 26, 2025, under application number 19063574.

Substituted Heterocycle Fused Gamma-Carbolines Synthesis

The USPTO published patent application US20260098040A1 for improved synthesis methods of substituted heterocycle fused gamma-carbolines, filed by inventor Peng Li on April 11, 2025. The application was published April 9, 2026. The document discloses synthesis methods, intermediates, and production processes for these heterocyclic compounds. No regulatory action or compliance obligations are imposed by this publication.

Nonlinear Optical Chromophores with High Steric Hinderance Substituents for Electro-Optic Devices

Lightwave Logic, Inc. published patent application US20260098206A1 covering nonlinear optical (NLO) chromophores with donors having high steric hindrance substituents, compositions/materials comprising such chromophores, and methods of making and using them in electro-optic devices. The application includes methods of drying and poling, and uses in EOMs. Inventors: Ginelle A. Ramann, Barry L. Johnson, Harvey F. Fulo, Will D. Mikkelsen-Yi.

KRAS Modulating Compounds

USPTO published patent application US20260098049A1 for KRAS modulating compounds useful as KRAS inhibitors. The application covers compounds, methods of making and using them, and pharmaceutical compositions. Filed August 11, 2025, with 19 inventors listed.

Lightwave Logic NLO Chromophores 3-Aminocyclohex-2-en-1-one Donor Groups

USPTO published patent application US20260099078A1 by Lightwave Logic, Inc. for nonlinear optical chromophores containing 3-aminocyclohex-2-en-1-one based donor groups. The application covers compositions, materials, and resistive layers comprising these NLO chromophores, methods of making and using them including drying and poling processes, and applications in electro-optic devices such as electro-optic modulators.

Rifabutin Analogs for Treatment of M. abscessus Bacterial Infections

USPTO published patent application US20260098046A1 for new rifabutin analog compounds and pharmaceutical compositions for treating bacterial infections, with particular focus on non-tuberculous mycobacteria including M. abscessus. The application was filed on September 29, 2023 by a team of nine inventors. This is a published patent application, not a granted patent.

Crystalline Form Patent, Tetracyclic Carboxamide, Apr 09

Crystalline Form Patent, Tetracyclic Carboxamide, Apr 09

Light-Emitting Heterocyclic Compound for Electronic Devices

USPTO published patent application US20260101670A1 for a heterocyclic compound (Formula 1) for use in light-emitting devices and electronic apparatus. The compound is incorporated into the interlayer and emission layer between electrodes. Inventors: Hwasook Ryu, Hankyu Pak, Dongjun Kim, Chaeyeong Kim, Sanghyun Han. Filing date: March 24, 2025.

Improved Process for Preparing Risdiplam and Its Intermediates

The USPTO published patent application US20260098048A1 for an improved chemical synthesis process for Risdiplam, a pharmaceutical compound used to treat spinal muscular atrophy. The application also discloses novel intermediates involved in the preparation process. This is a routine patent publication that does not create immediate compliance obligations.

Anti-Giardial Heterocyclic Compounds for Parasitic Infections

USPTO published patent application US20260098047A1 covering heterocyclic compounds of Formula (I) and (II) for treatment and prevention of Giardiasis (parasitic infection). The application names four inventors and includes pharmaceutical composition claims and methods of using the compounds.

Jacobio Pharmaceuticals Patent on Solid Forms of Compound I or Salts Thereof

USPTO published Jacobio Pharmaceuticals' patent application (US20260098039A1) for solid forms of Compound I, a potential cancer therapeutic compound, and its salts. The patent covers novel solid forms, preparation methods, pharmaceutical compositions, and therapeutic uses. The application was filed August 16, 2023, and published April 9, 2026.

Yuhan Corporation Patent for Glucosylceramide Synthase Inhibitors

USPTO published patent application US20260098038A1 by Yuhan Corporation for novel 2,3-dihydro-1H-indene and 2,3-dihydrobenzofuran derivatives as glucosylceramide synthase (GCS) inhibitors. The compounds are intended for treating lysosomal storage disorders including Gaucher disease and Fabry disease, as well as neurodegenerative conditions such as Parkinson's disease and Tay-Sachs disease.

Multi-Fused Ring Compound for Diabetes, Obesity

USPTO published patent application US20260098037A1 for a multi-fused ring compound targeting diabetes and obesity. The application (filed September 22, 2025 by inventors Baomin Liu, Yan Zhu, Jinfa Hu, and Yu Huang) claims a compound of formula (I), its stereoisomers, and pharmaceutical compositions containing the compound for treating metabolic diseases. This is a routine patent publication providing public notice of the pending application and its claimed scope.

Heteroaryl Pyridazine Carboxamides For Cancer Treatment

The USPTO published patent application US20260098036A1 filed by Deutsches Krebsforschungszentrum covering 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds for cancer treatment. The application claims novel chemical compounds, methods of preparation, pharmaceutical compositions, and methods of treating cancer and disorders associated with aberrant AHR signaling.

Salts and Solid Forms of Piperidine-2,6-Dione for Treating Disorders

USPTO published patent application US20260098035A1 on April 9, 2026, covering novel salts and solid forms of (S)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. Inventors Lianfeng HUANG, Daozhong ZOU, and Tsz Chung LAI filed the application on September 19, 2023, claiming pharmaceutical compositions for treating, preventing, and managing various disorders.

2H-Benzotriazole Derivative for Treating Premature Ejaculation

USPTO published patent application US20260098034A1 for a 2H-benzotriazole derivative compound and pharmaceutical composition for treating premature ejaculation. The novel benzisothiazole compound demonstrated superior anti-premature ejaculation activity compared to dapoxetine in in-vivo testing. Six inventors are listed with a filing date of August 23, 2023.

Novel Crystalline Form of Enavogliflozin and Preparation Method

The USPTO published patent application US20260098033A1 for a novel crystalline form of enavogliflozin, an SGLT2 inhibitor for diabetes treatment. The new form exhibits improved thermodynamic stability, reduced hygroscopicity, enhanced long-term storage characteristics, and faster drug absorption compared to prior known forms. The application includes the preparation method and covers pharmaceutical compositions containing the crystalline form.

Methods and Compounds for Restoring Mutant p53 Function

USPTO published patent application US20260098032A1 disclosing compounds that bind mutant p53 proteins and restore their wild-type DNA-binding and tumor-suppressor activity. The compounds are directed at reducing cancer progression in tumors harboring p53 mutations. The application was filed on 2025-05-15 under CPC classes C07D 405/14 and related organic chemistry subclasses.

Shionogi Monocyclic GLP-1 Receptor Agonist Patent Application

Shionogi & Co., Ltd. filed USPTO Patent Application US20260098031A1 for a monocyclic compound demonstrating GLP-1 receptor agonist activity, along with pharmaceutically acceptable salts. The compound, classified under CPC codes C07D 405/14 and A61K 31/4439, is intended for pharmaceutical use. The application, published April 9, 2026, claims priority to the September 2023 filing date.

6-Aryl Isoindolin-1-ones mGlu2 Modulators, Apr 09

6-Aryl Isoindolin-1-ones mGlu2 Modulators, Apr 09

Amgen KIF18A Kinase Inhibitor Patent Application for Cancer Treatment

USPTO published Amgen's patent application US20260098029A1 for KIF18A protein-modulating compounds intended to treat cancer and cancer-related diseases. The application discloses compounds of formula (I) with synthetic intermediates, pharmaceutical compositions, and methods of treatment. The 15 named inventors include researchers from Amgen's medicinal chemistry and oncology teams.

Bristol-Myers Squibb Hemoglobinopathy Treatment Compounds

USPTO published patent application US20260098028A1 by Bristol-Myers Squibb Company covering compounds for treatment of hemoglobinopathies. The application includes claims for pharmaceutical compositions and methods of preventing or treating these blood disorders. The A1 publication followed a September 2025 filing date with European application number 19328416.

Pharmaceutically Acceptable Salt and Crystal Form of Tetrahydronaphthalene Derivative

USPTO published patent application US20260098027A1 for a pharmaceutically acceptable salt and crystal form of a tetrahydronaphthalene derivative, specifically covering (S)-3-(5-(4-((1-(4-((1R,2R)-6-hydroxy-2-isobutyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and its preparation method. Inventors include Lina Jia, Junran Yang, Zhenxing Du, Lin Wang, Qiyun Shao, and Jun Feng.

M4 Receptor Activators Treat Alzheimer's Parkinson's Schizophrenia

The USPTO published patent application US20260098026A1 for M4 receptor activator/modulator compounds of Formula I, filed September 15, 2023. The compounds are intended for treating M4-mediated neurological disorders including Alzheimer's Disease, Parkinson's Disease, schizophrenia, pain, addiction, and sleep disorders. The application covers the compounds, N-oxides, salts, preparation processes, intermediates, and pharmaceutical compositions.

Dimeric GYS1 Inhibitor Compounds for Metabolic Disorder Treatment

USPTO published patent application US20260098025A1 covering dimeric compounds of formula (I) as inhibitors of glycogen synthase 1 (GYS1), along with methods of preparing the compounds and methods of treating GYS1-mediated diseases, disorders, or conditions. The application names nine inventors including David John Morgans Jr. and Christopher Joseph Sinz, with an original filing date of September 13, 2023.

PARP1 Inhibitors and Uses Thereof

USPTO published patent application US20260098024A1 disclosing PARP1 inhibitor compounds and pharmaceutical compositions for cancer treatment. The application, filed on January 26, 2023 under application number 18833362, names six inventors including Robert L. Hoffman and Stephen W. Kaldor and covers compounds classified under C07D 401/12 and C07D 471/04.

Rhodium Catalyst Method for Hydrogenation of Furfural to Bio-Fuel

The USPTO published patent application US20260098023A1 by King Fahd University of Petroleum and Minerals, covering a method for hydrogenating furfural to furfuryl ethyl ether bio-fuel using a rhodium nanoparticle catalyst (0.9-1.1 wt.% on alumina). The reaction achieves at least 99% conversion and 99% selectivity under ethanol and hydrogen atmosphere.

MITSUI CHEMICALS Carbamate Compound Patent Application

MITSUI CHEMICALS, INC. published a patent application (US20260098022A1) for a carbamate compound with specific molecular structure parameters. The application describes compounds where R1-R4 form monocyclic or polycyclic rings through various substituent linkages. CPC classifications include C07D 295/205, C07C 271/44, and C07C 275/32. Competitors developing similar chemical structures should review claims upon grant.

NSAID Conjugate Anti-Inflammatory Compounds Via Microwave Synthesis

The USPTO published patent application US20260098019A1 for microwave-synthesized NSAID conjugate compounds containing triazolyl heterocycles. The compounds are derivatives of FDA-approved anti-inflammatory drugs such as ibuprofen and indomethacin. The application claims improved anti-inflammatory efficacy with reduced ulcerogenic effects and selective COX-2 inhibition over COX-1.

Bicyclic 1,4-Diazepanones and Therapeutic Uses

The USPTO published patent application US20260098018A1 disclosing bicyclic 1,4-diazepanone compounds of formula (I) and their therapeutic uses for treating diseases responsive to modulation of skeletal sarcomere contractility. The application names 15 inventors and was filed July 7, 2025 under Application No. 19261878.

Novel Aromatic Ring Derivative Containing Amide Substitution as TYK2 Inhibitor

The USPTO has published patent application US20260098017A1 for a novel aromatic ring derivative containing amide substitution as a TYK2 inhibitor for treating inflammatory and autoimmune diseases including psoriasis, psoriatic arthritis, dermatitis, lupus, inflammatory bowel disease, and rheumatoid arthritis. The application was filed December 22, 2023, with inventors including Wenzhi Wang, Shuangyong Sun, and colleagues. The invention demonstrates therapeutic efficacy in psoriasis and asthma animal models with good druggability, stability, and safety profiles.

Method and System for Fully Continuous-Flow Preparation of Nitroimidazole Antimicrobial Agent

USPTO published patent application US20260098016A1 for a fully continuous-flow method of synthesizing nitroimidazole antimicrobial agents. The method uses glyoxal aqueous solution, acetaldehyde aqueous solution, and ammonium hydroxide as raw materials through multi-step chemical reactions. Inventors include Fener Chen, Minjie Liu, Li Wan, Yajiao Zhang, Xingpeng Cai, and Zhisheng Yang. The system includes micromixers, microreactors, back pressure valves, gas-liquid separators, and online solvent switching units.

Crystalline Imidazole Polymorphs for Mitochondria and Cardiovascular Treatment

USPTO published patent application US20260098015A1 for crystalline polymorphic forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole. The compound is directed to treating mitochondria-related disorders and cardiovascular disorders or conditions. The application was filed May 19, 2025 and names Muralikrishna DUVVURI, Donald Herbert LAMUNYON, and Micah Jeffrey BODNER as inventors.

Ionizable Lipidoid Compositions and Therapeutic Uses Thereof

Ionizable Lipidoid Compounds for Therapeutic Agent Delivery

Dextrorphan Amino Acid Ester Stereoisomer Conjugates with Improved Bioavailability

The USPTO published patent application US20260098013A1 disclosing amino acid ester conjugates of dextrorphan using diastereomerically pure amino acids to improve bioavailability. Inventors include Sven Guenther, Travis Mickle, Sanjib Bera, and Amarraj Chakraborty. The application covers pharmaceutical compositions and methods of treating diseases using these conjugates.

Tetrahydroacridinone Analogues for Malaria Treatment and Prevention

The USPTO published patent application US20260098012A1 for tetrahydroacridinone scaffold molecules exhibiting antimalarial activity against multiple Plasmodium spp. strains in erythrocytic and exoerythrocytic stages. The application, filed December 11, 2025, names 11 inventors including Dennis E. Kyle and Steven Maher and covers pharmaceutical compositions for malaria treatment and prevention.

Deuterated Organic Compounds for Schizophrenia and Depression Treatment

The USPTO published patent application US20260098011A1 covering deuterated organic compounds of Formula I and II for modulating dopamine and serotonin neurotransmission. The compounds are directed toward treating disorders including schizophrenia and depression. The application was filed on June 11, 2025, under application number 19235237.

Heterocyclic JAK Inhibitors and Canine Atopic Dermatitis Treatment

The USPTO published patent application US20260092070A1 filed by Andrew Antony Calabrese and David T. Stanton for heterocyclic compounds that inhibit Janus Kinase 1 (JAK-1) enzymes. The compounds are designed for treating inflammatory disorders in non-human mammals, specifically canine atopic dermatitis. The application was filed December 2, 2025, under Application No. 19405620.

SMARCA2/4 Degrader Compounds and Compositions Patent

USPTO published patent application US20260092071A1 for compounds of Formula II as SMARCA2 or SMARCA4 degraders, including their pharmaceutical compositions and uses. The application (No. 19112750) was filed on September 22, 2023, with 14 inventors including Shaomeng Wang and colleagues. This is a publication of a patent application in the field of heterocyclic compounds for potential therapeutic use.